These mice show remarkably reduced brain size and body weight, severe ataxia, and neonatal death.
These include very low birth weight, severe jaundice [ 6], hypoxia, medication [ 7] and infection [ 8].
Main findings were: Low carcass weight, severe muscle atrophy, hemosiderosis in liver and spleen, subcutaneous oedema (18%) and effusions to body cavities (18%).
Other factors associated with developmental defects include: ingestion of chemicals (fluorides, tetracyclines, dioxins, thalidomide); prematurity/low birth weight; severe malnutrition, neonatal hypocalcemia, vitamin D deficiency; bilirubinemia, thyroid and parathyroid disturbances; maternal diabetes; neonatal asphyxia; severe infections; and metabolic disorders.
This is the first study finding a significantly increased incidence for type II diabetes in obese and overweight severe asthmatic patients in comparison to normal weight severe asthmatic patients.
In addition, a study in Tanzania on pregnancy outcomes found that multivitamins decreased the risk of low birth weight, severe preterm birth, and fetal death while increasing CD4, CD8, and CD3 lymphocytes [ 71].
Secondary outcomes were onset of labour, analgesia, blood loss, management of third stage of labour, perineal trauma, transfer, neonatal resuscitation, breastfeeding, gestational age at birth, birth weight, severe morbidity and mortality.
The oral corticosteroids requirement during the previous year and the long acting beta2-agonists (LABA) treatment were significantly higher (P = 0.029 and P = 0.027, resp). in obese than in overweight and in normal weight severe asthmatics (Table 1).
Patient characteristics such as duration of hospitalization, age, prematurity or low birth-weight, severe immuno-deficiencies and absence/presence of underlying medical conditions have been previously reported as risk factors for hospital-acquired RV infection [ 19].
whereas the score of Asthma Control Questionnaire, the number of asthma exacerbations during last year, the oral corticosteroids requirement during the previous year, and the LABA treatments are higher in obese than in overweight and normal weight severe asthmatics.
